Targeted co-delivery of daunorubicin and cytarabine based on the hyaluronic acid prodrug modified liposomes  

作　　者：George Frimpong Boafo Yejiao Shi Qingqing Xiao Kosheli Thapar Magar Makhloufi Zoulikha Xuyang Xing Chao Teng Emmanuel Brobbey Xiaotong Li Xiaohong Jiang Xiaochun Wang Yi Yang Samuel Kesse Wei He 

机构地区：[1]Shanghai Skin Disease Hospital,Tongji University School of Medicine,Shanghai 200443,China [2]Department of Pharmaceutics,School of Pharmacy,China Pharmaceutical University,Nanjing 211198,China [3]Institute of Translation Medicine,Shanghai University,Shanghai 200444,China

出　　处：《Chinese Chemical Letters》2022年第10期4600-4604,共5页中国化学快报（英文版）

基　　金：supported by the National Natural Science Foundation of China(Nos.81872823 and 82073782);the Double First-Class(No.CPU2018PZQ13)of the China Pharmaceutical University;the Shanghai Science and Technology Committee(No.19430741500);the Key Laboratory of Modern Chinese Medicine Preparation of Ministry of Education of Jiangxi University of Traditional Chinese Medicine(No.zdsys-202103)。

摘　　要：Breast cancer is the most prevalent cancer in women,and it was hard to prevent or diagnose at an early stage.Thus,it is imperative to develop advanced therapeutics for effective treatment.Herein,a targeted daunorubicin(DNR)and cytarabine(ara-C)co-delivery system was developed by modifying the ara-C loaded liposomes(LIP-ara-C)with the hyaluronic acid-DNR(HA-DNR)prodrugs.The co-assembled hybrid nanoparticles(HA-DNR/LIP-ara-C HNPs)exhibited good serum and storage stability with an average diameter of approximately 100 nm.By specifically binding to the CD44 receptors that overexpressed on cancer cells,these HNPs could be uptake via endocytosis and accumulate intracellularly,in which an optimized DNR and ara-C combination at a molar ratio of 1:5 could generate enhanced synergistic effects with reduced dose-related toxicity on cancer cells.

关 键 词：Breast cancer DAUNORUBICIN CYTARABINE CO-DELIVERY Liposomes 

分 类 号：TQ460.1[化学工程—制药化工] R737.9[医药卫生—肿瘤]